Arturo Araya, MBA, TrakCel, Cardiff, UK, describes challenges in supply chain management in the cell and gene therapy (CGT) sector. Due to the complexity of advanced therapies, there are multiple service providers contributing to each component of the product, resulting in a higher margin of error. A high cost of failure can also result in severe consequences if the therapy is administered to the wrong patient and manufacturing and supply chain capabilities can additionally be put under strain due to the sheer number of clinical trials occurring. This interview took place at Advanced Therapies Week 2022.